Back to discover
Disease

Pancreatitis

Late-stage therapeutic developmentEmerging researchCooling momentum
12
Publications
22
Clinical trials
4
Related conditions
1
Related proteins
2026
Latest publication
Current focus
P43220 biologyTherapeutic developmentDiagnosis & biomarkers

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Approval — Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed… (2019)

Clinical trials

16 sponsors · 2 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
22
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2019emaApprovalVolanesorsen sodium· Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

12 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20172026
Recent publications
Major themes8
  • Pancreatitis8
  • Diabetes Mellitus, Type 25
  • Glucagon-Like Peptide-1 Receptor Agonists4
  • Hypoglycemic Agents3
  • Incretins2
  • Antibiotic Prophylaxis1
  • Biomarkers1
  • Cholangiopancreatography, Endoscopic Retrograde1
Leading journals6
  • Current opinion in gastroenterology2
  • Gut2
  • Diabetes research and clinical practice1
  • Drugs1
  • Endocrinology, diabetes & metabolism1
  • Frontiers in endocrinology1
Leading researchers8
  • Beyer G2
  • Acosta RD1
  • Agrawal D1
  • Alam A1
  • Ammer-Herrmenau C1
  • Antweiler KL1
  • Asendorf T1
  • Beckingham I1
Affiliations (unnormalised)6
  • Adelaide Medical School1
  • AdventHealth Translational Research Institute1
  • Aintree University Hospital Liverpool1
  • and Nutrition. Ohio State University Wexner Medical Center1
  • Baylor University1
  • Baylor University Medical Center1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

4 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Pancreatitis is inflammation of the pancreas. It is classified as acute unless imaging shows chronic pancreatitis, and the common acute forms are alcoholic pancreatitis and gallstone pancreatitis. Acute pancreatitis is a common reason for hospital admission and can range from mild disease to severe illness with persistent organ failure.

Causes

The main causes described are gallstones and ethanol. Other noted causes include hypertriglyceridaemia, drugs, genetics, and ductal obstruction caused by calcification or neutrophil extracellular traps. Common bile duct stones can also lead to acute pancreatitis.

Pathophysiology

Acute pancreatitis is an inflammatory disorder of the pancreas associated with pancreatic injury and immune activation. The literature describes immune cell infiltration, especially neutrophils and M1 macrophages, and a disordered immune response that can drive systemic inflammatory response syndrome and systemic injury in severe disease. TLR4-mediated inflammatory signaling and NLRP3-inflammasome-related pathways are implicated in pancreatic damage and severe acute pancreatitis.

Risk factors

Gallstones and alcohol use are the most prominent risk factors in the supplied material. Hypertriglyceridaemia, drugs, and ductal obstruction are also noted, and common bile duct stones can predispose to acute pancreatitis. The literature also mentions genetics as a contributing factor.

Current standard of care

Management is described at the modality level as hospital-based supportive care with diagnostic evaluation and imaging to assess severity and complications. For pancreatitis related to common bile duct stones, endoscopic retrograde cholangiopancreatography, surgery, and radiological stone extraction are used. The literature also notes that treatment decisions depend on identifying complications and the underlying cause.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.